Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

1.96
+0.14007.69%
Post-market: 1.95-0.0099-0.51%19:53 EDT
Volume:876.77K
Turnover:1.68M
Market Cap:44.42M
PE:-0.15
High:1.97
Open:1.85
Low:1.82
Close:1.82
52wk High:10.99
52wk Low:1.79
Shares:22.66M
Float Shares:17.07M
Volume Ratio:0.86
T/O Rate:5.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0816
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-47.61%
PB:-0.13
PE(LYR):-0.11

Loading ...

Karyopharm Q1 net loss narrows

Reuters
·
May 14

Karyopharm Therapeutics Q1 EPS $(1.24) Beats $(1.40) Estimate, Sales $35.066M Beat $31.399M Estimate

Benzinga Earnings
·
May 14

Karyopharm Therapeutics Outlook FY Revenue USD 130-150 Million

THOMSON REUTERS
·
May 14

Karyopharm Therapeutics Q1 Net Income USD -22.392 Million

THOMSON REUTERS
·
May 14

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment

THOMSON REUTERS
·
May 14

Karyopharm Therapeutics Inc expected to post a loss of $1.43 a share - Earnings Preview

Reuters
·
May 12

Karyopharm management joins H.C. Wainwright BioConnect investor conference fireside chat

Reuters
·
May 12

Karyopharm to report Q1 2026 results, host conference call

Reuters
·
May 07

Karyopharm price target raised to $13 from $8 at H.C. Wainwright

TIPRANKS
·
May 07

Karyopharm Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 06

Karyopharm Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $13 From $8

THOMSON REUTERS
·
May 06

Karyopharm files to sell 8.84M shares of common stock for holders

TIPRANKS
·
May 05

BRIEF-Karyopharm Therapeutics May Offer Up To $400 Million In Securities - SEC Filing

Reuters
·
May 05

Karyopharm Therapeutics Inc - May Offer up to $400 Mln in Securities - SEC Filing

THOMSON REUTERS
·
May 05

Karyopharm Therapeutics Price Target Raised to $16.00/Share From $8.00 by Piper Sandler

Dow Jones
·
Apr 28

Karyopharm price target raised to $16 from $8 at Piper Sandler

TIPRANKS
·
Apr 27

U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global

Reuters
·
Apr 27

Karyopharm Therapeutics Inc : Piper Sandler Raises Target Price to $16 From $8

THOMSON REUTERS
·
Apr 27

Karyopharm Phase 3 SENTRY myelofibrosis trial results set for ASCO late-breaking oral presentation

Reuters
·
Apr 21

Karyopharm publishes corporate presentation highlighting Phase 3 selinexor readouts in myelofibrosis

Reuters
·
Apr 16